Predicts probability of acute urinary retention or surgical intervention within 2 years.
Predicts 5-year progression-free probability.
Predicts risk of additional node metastasis following complete axillary lymph node dissection.
Predicts 96-month disease-specific survival.
Predicts the 5- and 10-year recurrence-free survival percentage.
Predicts 10-year colorectal cancer risk.
Predicts 2-year and 5-year probabilities of freedom from seizure recurrence and probabilities of obtaining an Engel Score of 1.
Predicts risk of any adverse event, bothersome stress, urge incontinence or positive stress test with 12 months of surgery.
Predicts risk of urinary incontinence to help identify patients who may benefit from more aggressive management.
Predicts postpartum urinary and fecal incontinence.
Predicts 30-day transfusion probability.
Predicts 5- and 9-year disease-specific survival.
Predicts 30-day and 1-year risks of mortality, myocardial infarction, or revascularization.
Predicts the probability of cerebrovascular accidents using patient demographics and clinical characteristics.
Predicts 30-day all-cause mortality.
Predicts 3-, 5- and 10-year survival after exercise treadmill testing.
Predicts changes in semen parameters.
Predicts the 5-year graft survival and 1-year eGFR value.
Predicts 5- and 7-year freedom from recurrence and 7-year renal insufficiency.
Predicts 12-month progression-free survival with sunitinib or pazopanib.
Predicts the probability of malignant pathology for small renal masses.
Predicts the need of a patient to attend an extended care facility (ECF).
Predicts NAFLD histological score.
Predicts the probability of positive sentinel nodes.
Predicts 30-day probability of venous thromboembolisms(VTEs) post discharge.
Estimates the probability of presence of a serious adverse events.
Predicts 5-year percentage of recurrence-free survival to assist in determining the need for adjuvant treatment.
Predicts 5-year probability of survival.
Predicts 12-, 24- and 36-month survival.
Predict 5-year cancer specific survival and lymph node involvement.
Predicts percentage chance of having prostate cancer and of having high grade prostate cancer to help determine treatment options.
Determines 4-year probability of outcomes with or without dutasteride.
Predicts percentage of having prostate cancer with repeated prostate biopsy.
Predicts the probability of upgrading the Gleason score in patients with low- and intermediate-grade prostate cancer on biopsy to help identify patients who may benefit from more aggressive or novel therapy.
Predicts 5- and 10-year probabilities for radical prostatectomy, watchful waiting, and 3-dimensional conformal radiation therapy of survival, indolent cancer, freedom from recurrence, metastasis and trifecta.
Predicts 7-, 9- and 10-year post-treatment freedom from recurrence, and 10- and 15-year cancer-specific mortality.
Predicts 7- and 9-year post-treatment freedom from recurrence.
Predicts the probability of freedom from biochemical failure at 5- and 10-year and cumulative incidence of metastasis at 5- and 10-year for men receiving salvage radiation therapy.
Predicts 5-, 10- and 15-year prostate cancer-specific mortality.
Predicts 1- and 2-year overall survival.
Predicts the conversion to psychosis for youth who are at high risk due to symptoms, genetic risk, and recent decline in functioning based on a variety of tests and psychometric dimensions.
Predicts postoperative rates of 12-year sarcoma-specific mortality.
Predicts 1-, 2- and 3-year risk of sarcoma-specific death following local recurrence.
Predicts 30-day infection risk of organ space surgical site infection.
Predicts probability of emergency department visit within 30 days, readmission within 30 days and reoperation for infection within 90 days. Predicts change in EQ-5D, PHQ-9 and PDQ quality-of-life metrics.
Predicts probability of thyroid cancer in thyroid nodules.
Predicts length of stay and chance of NOT returning home.
Predicts 6-year mortality.
Predicts 7-year pouch retention probability.
© 2016 Cleveland Clinic Lerner Research Institute